5 Mid Cap Stocks Just Made New 52-Week Highs
A small list of companies at their highest prices of the year is entirely concentrated in one part of the market.
The strongest one-month run on the list belongs to 10x Genomics (TXG), up 33.4% over the last month, a sharp contrast to the S&P 500 return of +1.0% over the same period. As of Friday, September 25, there are 5 Mid Cap US and Canada-listed stocks in the Trefis coverage universe trading at their 52-week highs.
Every name on the list is from the Health Care sector. When a list of new highs is this narrow, the key question is whether the underlying business performance justifies the price.
The Complete 52-Week-High List
Here are all 5 names, sorted by market capitalization, with returns over four windows:
| Tickers | Market Cap |
1D % Chg |
1W % Chg |
1M % Chg |
1Y % Chg |
|---|---|---|---|---|---|
| BIIB | $33.62 Bil | 0.5% | 5.6% | 3.0% | 65.3% |
| VTRS | $20.74 Bil | 2.4% | 5.2% | 5.8% | 90.1% |
| RVTY | $16.86 Bil | 0.3% | 5.3% | 19.6% | 79.3% |
| TECH | $11.34 Bil | 0.1% | 0.3% | 0.3% | 42.6% |
| TXG | $11.14 Bil | 1.9% | 11.9% | 33.4% | 610.7% |
This screen covers US and Canada-listed stocks in the Trefis coverage universe. Mid Cap here means a market value between $10 billion and $40 billion, the upper figure excluded.
Which names show the gap between price and performance?
The run in 10x Genomics (TXG) has not been matched by its recent business results. Over the last twelve months, its revenue declined 4.3%, and its operating margin was -14.9%.
Revvity (RVTY) also made the list after a 19.6% gain over the last month. It trades at 71.0 times trailing earnings, and its revenue grew 4.1% over the last twelve months, and its operating margin was 12.3%.
How should a disciplined reader treat a 52-week-high list?
A stock trading at its highest price of the year is a sign of strength, and that strength can persist. But a high price is not a verdict on a company’s quality or a guarantee of future returns.
The disciplined move is to treat the list as a screen, not a recommendation. It is a starting point for research. The essential work is to check whether the business itself, through its growth and margins, earns the level the market has priced it at.
A new high tells you what the market already believes. The harder question is which of these runs management itself is underwriting. Our Guidance Momentum screen tracks exactly that: stocks where the company raised its own forward numbers.
New Highs Fade. Discipline Compounds
Some of the names on this list will keep setting highs for years, and some are at the top of their run right now. Sorting one from the other, name by name, every day, is the work most investors never keep up with.
That sorting is what the Trefis High Quality (HQ) Portfolio does systematically: about 30 quality businesses screened for the fundamentals that sustain a run, held with rules instead of excitement. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Use the high list for ideas; use the portfolio for the compounding.